GRI
Price
$1.39
Change
-$0.06 (-4.14%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
3.26M
INAB
Price
$0.12
Change
-$0.00 (-0.00%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
329.77M
63 days until earnings call
Interact to see
Advertisement

GRI vs INAB

Header iconGRI vs INAB Comparison
Open Charts GRI vs INABBanner chart's image
GRI Bio
Price$1.39
Change-$0.06 (-4.14%)
Volume$299
Capitalization3.26M
IN8bio
Price$0.12
Change-$0.00 (-0.00%)
Volume$2.45K
Capitalization329.77M
GRI vs INAB Comparison Chart
Loading...
GRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRI vs. INAB commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRI is a Hold and INAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (GRI: $1.39 vs. INAB: $0.12)
Brand notoriety: GRI and INAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GRI: 10% vs. INAB: 98%
Market capitalization -- GRI: $3.26M vs. INAB: $329.77M
GRI [@Biotechnology] is valued at $3.26M. INAB’s [@Biotechnology] market capitalization is $329.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRI’s FA Score shows that 2 FA rating(s) are green whileINAB’s FA Score has 1 green FA rating(s).

  • GRI’s FA Score: 2 green, 3 red.
  • INAB’s FA Score: 1 green, 4 red.
According to our system of comparison, GRI is a better buy in the long-term than INAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRI’s TA Score shows that 4 TA indicator(s) are bullish while INAB’s TA Score has 5 bullish TA indicator(s).

  • GRI’s TA Score: 4 bullish, 3 bearish.
  • INAB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, INAB is a better buy in the short-term than GRI.

Price Growth

GRI (@Biotechnology) experienced а +1.46% price change this week, while INAB (@Biotechnology) price change was -21.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

GRI is expected to report earnings on Mar 14, 2025.

INAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INAB($330M) has a higher market cap than GRI($3.26M). INAB YTD gains are higher at: -52.372 vs. GRI (-89.704). GRI has higher annual earnings (EBITDA): -7.87M vs. INAB (-23.92M). INAB has more cash in the bank: 11.9M vs. GRI (4.75M). GRI has less debt than INAB: GRI (131K) vs INAB (4.27M). GRI (0) and INAB (0) have equivalent revenues.
GRIINABGRI / INAB
Capitalization3.26M330M1%
EBITDA-7.87M-23.92M33%
Gain YTD-89.704-52.372171%
P/E Ratio0.03N/A-
Revenue00-
Total Cash4.75M11.9M40%
Total Debt131K4.27M3%
FUNDAMENTALS RATINGS
GRI: Fundamental Ratings
GRI
OUTLOOK RATING
1..100
2
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
98
P/E GROWTH RATING
1..100
3
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GRIINAB
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 29 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WTO0.940.03
+3.79%
UTime Limited
STOK10.940.04
+0.37%
Stoke Therapeutics
REG71.670.13
+0.18%
Regency Centers Corp
HBM9.370.01
+0.11%
Hudbay Minerals
ECBK15.57-0.06
-0.38%
ECB Bancorp

GRI and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRI has been loosely correlated with IDYA. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if GRI jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRI
1D Price
Change %
GRI100%
+7.41%
IDYA - GRI
54%
Loosely correlated
-2.50%
SNSE - GRI
40%
Loosely correlated
+4.14%
NLSP - GRI
38%
Loosely correlated
-9.95%
GOVX - GRI
37%
Loosely correlated
+6.67%
INAB - GRI
36%
Loosely correlated
-0.97%
More

INAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INAB has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INAB jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INAB
1D Price
Change %
INAB100%
-0.97%
IDYA - INAB
47%
Loosely correlated
-2.50%
SNSE - INAB
39%
Loosely correlated
+4.14%
GRI - INAB
36%
Loosely correlated
+7.41%
CUE - INAB
32%
Poorly correlated
-1.85%
SRZN - INAB
28%
Poorly correlated
-1.07%
More